Results 1 to 10 of about 158,362 (293)

Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy. [PDF]

open access: yesClinics (Sao Paulo), 2018
Platelet activating factor is a lipid mediator of inflammation, and in recent decades, it has emerged as an important factor in tumor outcomes. Platelet activating factor acts by specific binding to its receptor, which is present in both tumor cells and ...
da Silva Junior IA   +3 more
europepmc   +4 more sources

Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists. [PDF]

open access: yesMediators Inflamm, 2015
Chemotherapy is used to treat numerous cancers including melanoma. However, its effectiveness in clinical settings is often hampered by various mechanisms.
Sahu RP, Ferracini M, Travers JB.
europepmc   +5 more sources

Platelet-Activating Factor-Receptor and Tumor Immunity. [PDF]

open access: yesJSM Cell Dev Biol, 2014
First described in 1972 by Benveniste and colleagues, platelet-activating factor (PAF) remains one of the potent phospholipid known to date. The role of PAF produced enzymatically in mediating diverse biological and pathophysiological processes including
Sahu RP, Konger RL, Travers JB.
europepmc   +4 more sources

Biased signaling due to oligomerization of the G protein-coupled platelet-activating factor receptor. [PDF]

open access: yesNat Commun, 2022
The functional consequence of G protein-coupled receptor oligomerization remains debated. Here the authors show that platelet-activating factor receptor oligomerization enhances G protein coupling, and restrains β-arrestin recruitment and internalization.
Liu J   +11 more
europepmc   +2 more sources

Macrophage Derived Platelet Activating Factor Implicated in the Resolution Phase of Gouty Inflammation [PDF]

open access: yesInternational Journal of Inflammation, 2014
Human blood derived in vitro differentiated monocytes or macrophages are a population of cells which have been investigated over the years to determine the role these cells play in the resolution phase of gout.
Darshna Yagnik
doaj   +3 more sources

Bovine Respiratory Syncytial Virus Enhances the Adherence of Pasteurella multocida to Bovine Lower Respiratory Tract Epithelial Cells by Upregulating the Platelet-Activating Factor Receptor. [PDF]

open access: yesFront Microbiol, 2020
Coinfection by bovine respiratory syncytial virus (BRSV) and Pasteurella multocida (PM) frequently has been observed in cattle that develop severe pneumonia.
Sudaryatma PE   +6 more
europepmc   +2 more sources

A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment. [PDF]

open access: yesFront Neurol, 2018
Amyotrophic lateral sclerosis (ALS) is the third most prevalent neurodegenerative disease affecting upper and lower motor neurons. An important pathway that may lead to motor neuron degeneration is neuroinflammation.
Briones MRS   +5 more
europepmc   +2 more sources

Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death. [PDF]

open access: yesFront Oncol, 2018
Irradiation generates oxidized phospholipids that activate platelet-activating factor receptor (PAFR) associated with pro-tumorigenic effects. Here, we investigated the involvement of PAFR in tumor cell survival after irradiation. Cervical cancer samples
da Silva-Junior IA   +4 more
europepmc   +2 more sources

Platelet-Activating Factor Disrupts the Nasal Epithelial Barrier Independently of the Platelet-Activating Factor Receptor Pathway. [PDF]

open access: yesAllergy Asthma Immunol Res
Platelet-activating factor (PAF) mediates nasal congestion and rhinorrhea by affecting vascular permeability, but the underlying mechanisms remain unclear. Here, we sought to explore the effect of PAF on the nasal epithelial barrier in chronic rhinosinusitis with nasal polyps (CRSwNP).Human nasal epithelial cells (hNECs) were pre-treated with Apafant ...
Tan J   +7 more
europepmc   +3 more sources

Upregulated pneumococcal adhesion molecule (platelet-activating factor receptor) may predispose COPD patients to community-acquired pneumonia. [PDF]

open access: yesInt J Chron Obstruct Pulmon Dis, 2017
Shakti Dhar Shukla,1,2 Philip M Hansbro,1,2 Eugene Haydn Walters3 1School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, 2Hunter Medical Research Institute, New Lambton Heights, NSW, 3School of Medicine, University of ...
Shukla SD, Hansbro PM, Walters EH.
europepmc   +2 more sources

Home - About - Disclaimer - Privacy